Roche enters into definitive merger agreement to acquire Spark Therapeutics
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction. This corresponds to a total transaction value of approximately US$ 4.3 billion on a fully diluted basis.
Brilinta’s Phase III THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes
- Details
- Category: AstraZeneca
The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone.
Amgen, Cytokinetics and Servier announce start of METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment.
Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin
- Details
- Category: Novo Nordisk
Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLink[1] mobile app and LibreView[2] cloud-based system).
Ochsner Health System and Pfizer partner to develop innovative models for clinical trials
- Details
- Category: Pfizer
NEW ORLEANS & Ochsner Health System, Louisiana's largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials.
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This makes Egaten the only FDA-approved drug for people with this disease and is expected to facilitate broader access to this important drug not only in the US, but also in affected countries worldwide.
Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
- Details
- Category: Bayer
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization, including the U.S., for larotrectinib (VITRAKVI®) and BAY 2731954 (LOXO-195). Both compounds are being developed globally for the treatment of adult and pediatric patients with advanced solid tumors harboring NTRK gene fusions.
More Pharma News ...
- Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials
- Merz delivers double-digit growth in strategic business areas
- The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients
- Merck to expand US biopharmaceutical R&D facility to advance innovative clinical pipeline
- US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897
- Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes
- Pfizer receives positive CHMP opinion for Vizimpro® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations